By David Sachs


Lonza said its performance over the first quarter was soft but that it expects the first half to move in line with last year, and backed its full-year guidance.

The Swiss pharmaceutical company said Tuesday that it still expects flat sales growth at constant exchange rates for the year and core earnings before interest, taxes, depreciation and amortization margin in the high 20s.

Sales for the second half year are expected to be solid, reflecting the time of batch releases.

It didn't provide any actual figures for the first quarter.


Write to David Sachs at david.sachs@wsj.com


(END) Dow Jones Newswires

05-14-24 0138ET